ONL THERAPEUTICS

ONL Therapeutics (ONL) is a clinical-stage biopharmaceutical company committed to helping patients see the future. Our mission is to develop innovative therapeutics to protect and improve the vision of patients with a range of retinal disease and conditions... Based on its industry-leading expertise in retinal neuroprotection, ONL is developing first-in-class treatments for serious, vision-threatening retinal diseases and conditions. The company possesses a strong and wide-ranging intellectual property portfolio around both the Fas pathway and the composition of its drug candidates, as well as experienced management and expert advisory teams with decades of experience in drug development and retinal disease... ONL's lead therapeutic candidate, ONL1204, is a first-in-class small peptide Fas inhibitor designed to protect retinal cells from both death and inflammatory signaling pathways. ONL1204 Ophthalmic Solution is being developed for the treatment of retinal detachment, an acute..

Also known as: ONL Therapeutics, Inc.

Primary location: Ann Arbor United States